These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 29330212)

  • 41. Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer.
    Yılmaz M; Erdiş E; Uçar M; Demir N; Alandağ C; Yücel B
    Jpn J Clin Oncol; 2024 May; 54(5):521-529. PubMed ID: 38336481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
    Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
    Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unique characteristics and failure patterns of metaplastic breast cancer in contrast to invasive ductal carcinoma: a retrospective multicenter case-control study (KROG 13-07).
    Yu JI; Choi DH; Huh SJ; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Kim JH; Cho J; Kim IA; Lee JH; Park W
    Clin Breast Cancer; 2015 Apr; 15(2):e105-15. PubMed ID: 25459069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
    Klar N; Rosenzweig M; Diergaarde B; Brufsky A
    Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
    Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
    Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
    Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
    Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
    Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
    Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
    Montagna E; Maisonneuve P; Rotmensz N; Cancello G; Iorfida M; Balduzzi A; Galimberti V; Veronesi P; Luini A; Pruneri G; Bottiglieri L; Mastropasqua MG; Goldhirsch A; Viale G; Colleoni M
    Clin Breast Cancer; 2013 Feb; 13(1):31-9. PubMed ID: 23098574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women.
    Keegan TH; Press DJ; Tao L; DeRouen MC; Kurian AW; Clarke CA; Gomez SL
    Breast Cancer Res; 2013; 15(5):R95. PubMed ID: 24131591
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
    Ogiya R; Sagara Y; Niikura N; Freedman RA
    Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma.
    Wu SG; Yang SP; Zhang WW; Wang J; Lian CL; Chen YX; He ZY
    Sci Rep; 2020 Dec; 10(1):22070. PubMed ID: 33328559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
    Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
    Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.